ALKS - Alkermes plc
| Previous Close | 34.55 |
| Open | 34.36 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 34.13 - 35.30 |
| 52 Week Range | 27.54 - 61.21 |
| Volume | 634,171 |
| Avg. Volume | 838,805 |
| Market Cap | 5.452B |
| Beta (3Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.90 |
| Earnings Date | Apr 24, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.00 |
- Zacks•17 hours ago
Alkermes Focuses on Pipeline, Depends on Partners for Funds
Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
- Business Wire•2 days ago
Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program
- Zacks•6 days ago
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•8 days ago
Alkermes plc’s (NASDAQ:ALKS) Path To Profitability
Alkermes plc's (NASDAQ:ALKS): Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland,Read More...
- Zacks•15 days ago
Allergan's Depression Candidate Fails in Studies, Stock Down
Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%
- Motley Fool•16 days ago
REVIEWAPALOOZA!: 5-Stock Samplers
Learning more about picking, about scoring, and about holding yourself accountable.
- PR Newswire•16 days ago
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference
DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on ...
- GlobeNewswire•22 days ago
Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•22 days ago
Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates
Key highlights of the past week are merger agreements, and regulatory and pipeline developments.
- Zacks•24 days ago
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.
- PR Newswire•24 days ago
Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
DUBLIN, Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. The study will explore the safety, tolerability and efficacy of ALKS 4230 administered subcutaneously and assess once-weekly and once-every-three-week dosing schedules.
- GlobeNewswire•24 days ago
CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Feb. 25, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•24 days ago
FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc. ("Alkermes" or the "Company") ...
- GlobeNewswire•24 days ago
CLASS ACTION UPDATE for YRIV, ALKS, MKL and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Feb. 25, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•25 days ago
FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc. ("Alkermes" or the "Company") ...
- GlobeNewswire•25 days ago
CLASS ACTION UPDATE for DBVT, ALKS, GSM and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Feb. 25, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•25 days ago
DEADLINE ALERT - IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can ...
- PR Newswire•25 days ago
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
DUBLIN and CAMBRIDGE, Mass., Feb. 25, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™, which has been conditionally accepted by the FDA and will be confirmed upon approval.
- ACCESSWIRE•25 days ago
DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019
NEW YORK, NY / ACCESSWIRE / February 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Alkermes plc, Inc. ("Alkermes" or the "Company") ...
- ACCESSWIRE•25 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline - ALKS
NEW YORK, NY / ACCESSWIRE / February 24, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc. (''Alkermes'' or the ''Company'') (ALKS) and certain of its officers and directors. The class action, filed in United States District Court, Eastern District of New York, and indexed under 19-cv-00624, is on behalf of a class consisting of all behalf of persons and/or entities who purchased or otherwise acquired Alkermes securities between February 17, 2017 through November 1, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- GlobeNewswire•25 days ago
CLASS ACTION UPDATE for DNKEY, ALKS, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Feb. 24, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•26 days ago
IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC Class Action Update
NEW YORK, NY / ACCESSWIRE / February 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can ...
- GlobeNewswire•26 days ago
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALKS, GSM, UXIN and AVP
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- GlobeNewswire•27 days ago
CLASS ACTION UPDATE for ALKS, MU, SVXY and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Feb. 22, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
